Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis
- PMID: 15329364
- DOI: 10.1093/jac/dkh411
Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis
Abstract
Objectives: This study was carried out to explore lectin-functionalized poly (lactide-co-glycolide) nanoparticles (PLG-NPs) as bioadhesive drug carriers against tuberculosis (TB), in order to reduce the drug dosage frequency of antitubercular drugs and thus improve patient compliance in TB chemotherapy.
Methods: Wheat germ agglutinin (WGA)-coated PLG-NPs were prepared by a two-step carbodiimide procedure. This formulation was administered to guinea pigs through the oral/aerosol route for a detailed pharmacokinetic and chemotherapeutic evaluation. Immunological or hepatotoxic effects of WGA lectin, if any, were also determined.
Results: WGA-functionalized PLG-NPs were in the size range of 350-400 nm, with binding of 3-3.5 microg of WGA/mg of PLG-NPs and drug encapsulation efficiency of 54%-66%. Upon administration of lectin-coated PLG-NPs through the oral/aerosol route, the presence of drugs in plasma was observed for 6-7 days for rifampicin and 13-14 days for isoniazid and pyrazinamide. However, upon administration of uncoated PLG-NPs (oral/aerosolized) rifampicin was detectable in plasma for 4-6 days, whereas isoniazid and pyrazinamide were detectable for 8-9 days. All three drugs were present in lungs, liver and spleen for 15 days. Administration of WGA-coated PLG-NPs caused a significant (P < 0.001) increase in the relative bioavailability of antitubercular drugs. Chemotherapeutic studies revealed that three doses of oral/nebulized lectin-coated nanoparticles fortnightly could yield undetectable mycobacterial colony forming units (cfu); this was achievable with 45 doses of oral free drugs.
Conclusion: WGA-functionalized PLG-NPs could be potential drug carriers for antitubercular drugs through the oral as well as aerosol route for effective TB control.
Similar articles
-
Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model.J Antimicrob Chemother. 2004 Jul;54(1):266-8. doi: 10.1093/jac/dkh260. Epub 2004 May 5. J Antimicrob Chemother. 2004. PMID: 15128731
-
Oral poly(lactide-co-glycolide) nanoparticle based antituberculosis drug delivery: toxicological and chemotherapeutic implications.Indian J Exp Biol. 2006 Jun;44(6):459-67. Indian J Exp Biol. 2006. PMID: 16784116
-
Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis.Int J Antimicrob Agents. 2005 Oct;26(4):298-303. doi: 10.1016/j.ijantimicag.2005.07.012. Int J Antimicrob Agents. 2005. PMID: 16154726
-
Nanotechnology based drug delivery system(s) for the management of tuberculosis.Indian J Exp Biol. 2006 May;44(5):357-66. Indian J Exp Biol. 2006. PMID: 16708887 Review.
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
Cited by
-
Nanobead-based interventions for the treatment and prevention of tuberculosis.Nat Rev Microbiol. 2010 Nov;8(11):827-34. doi: 10.1038/nrmicro2437. Epub 2010 Oct 12. Nat Rev Microbiol. 2010. PMID: 20938454 Free PMC article. Review.
-
A Novel Preparation Technique for Human Nasal Respiratory Mucosa to Disclose Its Glycosylation Pattern for Bioadhesive Drug Delivery.Pharmaceutics. 2023 Mar 17;15(3):973. doi: 10.3390/pharmaceutics15030973. Pharmaceutics. 2023. PMID: 36986834 Free PMC article.
-
Biomaterials-Based Opportunities to Engineer the Pulmonary Host Immune Response in COVID-19.ACS Biomater Sci Eng. 2021 May 10;7(5):1742-1764. doi: 10.1021/acsbiomaterials.0c01287. Epub 2020 Dec 27. ACS Biomater Sci Eng. 2021. PMID: 33356134 Free PMC article. Review.
-
Nanotechnological innovations in paediatric tuberculosis management: current trends and future prospects.Front Drug Deliv. 2024 Jan 8;3:1295815. doi: 10.3389/fddev.2023.1295815. eCollection 2023. Front Drug Deliv. 2024. PMID: 40838058 Free PMC article. Review.
-
Drug delivery systems: An updated review.Int J Pharm Investig. 2012 Jan;2(1):2-11. doi: 10.4103/2230-973X.96920. Int J Pharm Investig. 2012. PMID: 23071954 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous